GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Pancreatic Adenocarcinoma|Esophageal Adenocarcinoma|Esophageal Squamous Cell Carcinoma|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Triple Negative Breast Cancer|Castration-resistant Prostate Cancer|Microsatellite Stable Colorectal Cancer|Non-small Cell Lung Cancer|Small-cell Lung Cancer|Head and Neck Squamous Cell Carcinoma|Urothelial Carcinoma|Renal Cell Carcinoma|Hepatocellular Carcinoma
Interventions: DRUG: GB1275|DRUG: nab-paclitaxel and gemcitabine|DRUG: pembrolizumab
Sponsor: GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Collaborators: Merck Sharp & Dohme LLC